Intercontinental Exchange Inc (ICE) Stock News

Rosen Law Firm reminds Photronics, Inc. investors who purchased securities between December 10, 2025 and May 27, 2026 of the September 4, 2026 deadline to join a securities class action lawsuit. The lawsuit alleges that Photronics provided false and misleading statements about its high-end product pipeline and customer demand, while concealing a critical bottleneck in its design release pipeline that made forward growth expectations unachievable.

WisdomTree Multi Asset Issuer has announced an amendment to the Daily Swap Rate for its WisdomTree Silver 3x Daily Leveraged Securities, effective 1 December 2026. The rate will decrease from 0.01248% to 0.00692%, with amendment documents becoming effective on 1 September 2026. BNP Paribas acts as the Swap Provider for this change.

New America Acquisition I Corp. (NYSE: NWAX) announced leadership changes on August 26, 2026, with George O'Leary resigning as CFO and Tim S. Ledwick appointed as the new CFO and Christopher Devall as COO. Both new executives bring extensive experience in financial leadership and operations. The company continues its search for a business combination focused on American industrial strength and innovation.

Rosen Law Firm is notifying investors in EquipmentShare.com Inc, ARS Pharmaceuticals Inc, and Barclays PLC of ongoing securities class action lawsuits. EquipmentShare investors who purchased shares during the IPO or within the Class Period are encouraged to join the lawsuit, with a lead plaintiff deadline of September 21, 2026. The lawsuits allege material misstatements and omissions regarding business operations and financial disclosures.

Rosen Law Firm is notifying Microsoft investors of an August 11, 2026 deadline to join a securities class action lawsuit. The lawsuit alleges that Microsoft made false statements regarding its Copilot AI products, which allegedly experienced significant technical and market share problems, and that the company failed to disclose the need for billions in additional capital expenditures and GPU/CPU capacity diversion from Azure services to improve Copilot's competitive positioning.

Valeo SE has announced the exercise of its make-whole redemption option for €750 million in 5.375% Sustainability Linked Bonds due May 28, 2027. The early redemption is scheduled for August 24, 2026, with the redemption amount to be calculated and published by August 18, 2026. The bonds will be delisted from Euronext following redemption.

A securities class action lawsuit has been filed against BitGo Holdings, Inc. (NYSE: BTGO) alleging that offering documents and statements made during its January 2026 IPO and through May 2026 contained material misstatements and omissions. Specifically, the lawsuit claims BitGo understated risks from declining digital asset prices and made false statements about its financial performance and business prospects. Investors who purchased BTGO securities have until August 7, 2026 to become lead plaintiffs.

A class action lawsuit has been filed against Capricor Therapeutics for allegedly making false statements about its lead drug candidate Deramiocel. The FDA rejected the drug application after discovering undisclosed changes to the statistical analysis plan, causing Capricor's stock to plummet 64% on July 27, 2026, and an additional 36% on July 29, 2026, following an advisory committee vote against the drug's efficacy.

Rosen Law Firm announces a securities class action lawsuit against PicS N.V. (NASDAQ: PICS) regarding alleged false and misleading statements in its January 2026 IPO offering documents. The lawsuit claims PicS failed to disclose deficient credit evaluation procedures, material reclassifications of credit exposures, undisclosed heightened default rates, and deteriorating customer credit quality. The lead plaintiff deadline is August 4, 2026.

A class action lawsuit has been filed against Wix.com Ltd. for allegedly making false statements about its AI product offerings, overstating competitiveness and performance while understating development costs. The lawsuit covers securities purchased between February 19, 2025 and May 12, 2026. Multiple analyst downgrades and disappointing earnings reports triggered significant stock price declines, with the stock falling over 27% following Q1 2026 results that revealed weakness in the professional developer business and competitive challenges.

Rosen Law Firm has filed securities class action lawsuits against Futu Holdings Limited, First Solar, Inc., and PicS N.V., encouraging investors who purchased securities during specified class periods to join the litigation. The firm is seeking lead plaintiffs with an August 25, 2026 deadline for Futu and August 4, 2026 deadline for PicS.

A class action lawsuit has been filed against EquipmentShare.com, Inc. (EQPT) alleging the company made false and misleading statements regarding undisclosed related-party transactions in its January 2026 IPO. An Umibōzu Research report revealed that entities affiliated with company founders received at least $77 million through undisclosed transactions, causing the stock to fall over 6% on June 24, 2026. Investors with substantial losses can seek appointment as lead plaintiff by September 21, 2026.

Rosen Law Firm is reminding investors in Badger Meter, Inc. (NYSE: BMI) who purchased stock between April 18, 2024 and April 16, 2026 of the August 3, 2026 deadline to join a securities class action lawsuit. The lawsuit alleges that Badger Meter made materially false and misleading statements about its financial results by pulling forward customer orders to recognize revenue early, concealing weakening demand and deteriorating order trends.

Rosen Law Firm is notifying First Solar, Inc. investors who purchased securities between February 26, 2025 and February 24, 2026 of an August 24, 2026 deadline to join a securities class action lawsuit. The lawsuit alleges that First Solar made materially false and misleading statements regarding its capacity to manage U.S. tariff policy impacts, overstated performance projections, and failed to disclose negative effects from production facility underutilization and relocation efforts.

Moore Law PLLC is investigating Grindr Inc.'s $500 million stock repurchase program, alleging the board breached fiduciary duties by allowing buybacks to continue despite knowing they would push Chairman G. Raymond Zage III's ownership above 50% without requiring a control premium. The repurchases reduced outstanding shares to 187,032,103 by September 2025, increasing Zage's beneficial ownership to approximately 50.11%. Grindr stock has declined approximately 25% over the past 12 months.

Law firm Robbins Geller Rudman & Dowd LLP announced class action lawsuits against GRAIL, Inc. (NASDAQ: GRAL) for allegedly making false statements about its NHS-Galleri cancer screening trial. GRAIL failed to achieve the primary endpoint of reducing Stage III-IV cancers, causing the stock to fall over 50% on February 19, 2026. The firm is seeking lead plaintiffs from investors who purchased GRAL stock between May 13, 2025 and February 19, 2026. Similar lawsuits were also filed against Commvault Systems, Inc. and PicS N.V.

The article compares NICE and Twilio as investment options for 2026. NICE is recommended as the better choice due to its established profitability (20.8% net margin), lower valuation (Forward P/E of 9.0x), and proven cloud momentum across 150+ countries. While Twilio shows impressive headline revenue growth of 14%, the article argues this is inflated by carrier pass-through fees that don't contribute to gross profit, with underlying organic growth being more modest. NICE's steady execution and AI-embedded enterprise solutions are positioned as more attractive than Twilio's still-developing voice AI story.

Girard Sharp LLP is investigating potential securities claims on behalf of former Blue Owl Technology Finance Corp. II investors who received shares in the merger with Blue Owl Technology (NYSE: OTF) on March 24, 2025. Since the NYSE listing on June 13, 2025, Blue Owl Technology's share price has declined over 30%, with the investigation focusing on potential undisclosed issues with the fund's investment portfolios.

Video appears to show events around alleged ICE shooting in Maine  Reuters

A class action lawsuit has been filed against Erasca, Inc. alleging that the company and its executives made false and misleading statements regarding its ERAS-0015 drug candidate. The lawsuit claims preclinical data was based on improper comparisons to Revolution Medicines and lacked reasonable basis. Following disclosure of a patent infringement letter from Revolution Medicines and adverse Phase I clinical data including a patient death, Erasca's stock fell approximately 59% in total.

A securities class action lawsuit has been filed against Nano-X Imaging (NNOX) alleging the company made false statements about operational efficiency and product demand while concealing poor manufacturing alignment, increased cash burn, and restructuring risks. The lawsuit covers investors who purchased securities between March 31, 2025 and April 17, 2026. The deadline to seek lead plaintiff status is August 11, 2026. The action was triggered after Nano-X reported a $33.4 million net loss in Q4 2025, including a $17.5 million impairment charge related to restructuring at its Korean facility, causing the stock to fall 24.39%.

A federal securities class action has been filed against Grail, Inc. (NASDAQ: GRAL) alleging that company executives made false and misleading statements about the NHS-Galleri cancer detection trial's likelihood of success while concealing material adverse facts. On February 19, 2026, Grail announced the trial failed to achieve its primary endpoint, causing the stock to plummet 50.55% in a single day from $101.53 to $50.21 per share. Investors who purchased GRAL stock between May 13, 2025 and February 19, 2026 may be eligible to participate in the class action, with a deadline of August 4, 2026 to seek lead plaintiff appointment.

Faruqi & Faruqi, LLP is investigating securities fraud claims against Erasca, Inc. (NASDAQ: ERAS) for allegedly making false statements about its ERAS-0015 drug candidate based on improper comparisons to Revolution Medicines' compound. The company disclosed patent infringement allegations and a patient death in Phase 1 trials on April 27, 2026, causing the stock to plummet from $21.49 to $9.90 per share over two trading days. Investors who purchased ERAS securities between January 14, 2025 and April 26, 2026 can seek lead plaintiff status by August 10, 2026.

A securities class action lawsuit has been filed against Peabody Energy Corporation for allegedly making false and misleading statements about its Centurion mine operations. The company provided overly positive guidance while concealing material operational challenges. Stock price declined significantly following corrective disclosures on March 30, 2026 (down 9.7%) and May 5, 2026 (down 5.7%) when the company revealed commissioning delays and reduced output expectations. The deadline to seek lead plaintiff status is August 24, 2026.

A federal securities class action has been filed against Lucid Group alleging that the company and its executives made false and misleading statements by concealing a supplier quality issue that significantly disrupted Lucid Gravity deliveries and overstating manufacturing capabilities. The lawsuit covers investors who purchased LCID stock between February 25, 2026 and April 13, 2026. The deadline to seek lead plaintiff appointment is July 28, 2026.

A securities class action lawsuit has been filed against Embecta Corp. (NASDAQ: EMBC) alleging that the company made false and misleading statements about its financial guidance. Embecta's stock plummeted 57.8% on May 5, 2026, after the company disclosed a revenue decline of over 14% and cut its fiscal year 2026 guidance, primarily due to weakness in pen needle sales. The deadline to seek lead plaintiff status is August 17, 2026.

Faruqi & Faruqi, LLP is investigating a federal securities class action against GeneDx Holdings Corp. (NASDAQ: WGS) for allegedly making false and misleading statements about its Fabric Genomics acquisition and overstating the durability of reimbursement rates. On May 4, 2026, GeneDx disclosed missed Q1 results, cut 2026 guidance from $540-555M to $475-490M, and took a $31.3M goodwill impairment charge on the $36.5M Fabric Genomics acquisition. The stock fell 49% ($33.42 per share) on the news. The deadline to seek lead plaintiff appointment is August 3, 2026.

Rosen Law Firm reminds investors who purchased Lucid Group securities between February 25, 2026 and April 13, 2026 of the July 28, 2026 lead plaintiff deadline in a securities class action. The lawsuit alleges that Lucid made false statements regarding supplier quality issues that disrupted Lucid Gravity deliveries and overstated manufacturing capabilities, resulting in material negative impact on the company's business and financial results.

Moore Law PLLC is investigating ICON plc (NASDAQ: ICLC) following the company's announcement of an internal audit committee investigation into accounting practices and controls initiated in October 2025. ICON's stock price dropped significantly on February 12, 2026, when the company disclosed the investigation and delayed its earnings release to April 30, 2026.

Moore Law PLLC is investigating Veritone, Inc. for allegedly making false statements regarding revenue recording and misclassification of costs, resulting in overstated revenue and assets. The company disclosed on April 14, 2026, that previously issued financial statements should no longer be relied upon due to significant revenue overstatement and net loss understatement errors. Veritone's stock fell 29.5% following the March 26 announcement of accounting determination issues.